Type 2 diabetes articles for people who want clear, practical guidance on symptoms, diagnosis, blood sugar targets, medicines, food, activity, and long-term risk reduction.Start here for plain-language explainers, safety notes, and care-team questions. Use this information to prepare for conversations with a clinician, not to change prescribed treatment on your own.
A pediatric review found GLP-1 medicines may help selected children and teens with obesity or type 2 diabetes, but long-term safety data remain limited.
An ENDO 2026 real-world study linked semaglutide with fewer bone fractures than several other weight-loss medicines in adults with type 2 diabetes. The finding is interesting, but it does not prove semaglutide prevents fractures.
Phase 3 retatrutide data in recent-onset type 2 diabetes showed A1C lowering and weight loss. The drug remains investigational and is not FDA-approved.
A new FLOW analysis reports that semaglutide kidney and all-cause death benefits were consistent across cardiovascular-risk groups in adults with type 2 diabetes and chronic kidney disease.
